James Noble
2019
In 2019, James Noble earned a total compensation of $2.8M as Former Chief Executive Officer at Adaptimmune Therapeutics, a 7% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $254,727 |
|---|---|
| Option Awards | $1,917,220 |
| Salary | $606,492 |
| Other | $43,305 |
| Total | $2,821,743 |
Noble received $1.9M in option awards, accounting for 68% of the total pay in 2019.
Noble also received $254.7K in non-equity incentive plan, $606.5K in salary and $43.3K in other compensation.
Rankings
In 2019, James Noble's compensation ranked 4,328th out of 13,971 executives tracked by ExecPay. In other words, Noble earned more than 69.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,328 out of 13,971 | 69th |
Division Manufacturing | 1,589 out of 5,701 | 72nd |
Major group Chemicals And Allied Products | 557 out of 2,200 | 75th |
Industry group Drugs | 469 out of 1,886 | 75th |
Industry Biological Products, Except Diagnostic Substances | 100 out of 389 | 74th |
Source: SEC filing on April 20, 2020.
Noble's colleagues
We found four more compensation records of executives who worked with James Noble at Adaptimmune Therapeutics in 2019.